Follow all the latest from Fresenius Kabi biosimilars
Latest News
IDACIO® (adalimumab-aacf) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend®(pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia
Upcoming Events
HCP
October 23-25, 2023
Connect with us in St. Louis at the Fall Hospital Pharmacy Conference.
Chicago Race for the Cure
October 28, 2023
Connect with us in Chicago’s Soldier Field for the Susan G. Komen Race for the Cure.
ASHP Mid-Year
December 3-7, 2023
Connect with us in Anaheim at the American Society of Health-System Pharmacists Mid-year Meeting.
AIBD
December 14-16, 2023
See us in Orlando at the Advances in Inflammatory Bowel Diseases Conference.
Resources
- All Resources
- Guides
- Useful Links
- Videos
- Webinars
